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Abstract
Background: We aimed to evaluate the evolution and implementation of the massive
transfusion protocol (MTP) in an urban level 1 trauma centre. Most data on this topic
comes from trauma centres with high exposure to life-threatening haemorrhage. This study
examines the effect of the introduction of an MTP in an Australian level 1 trauma centre.
Methods: A retrospective study of prospectively collected data was performed over a
14-year period. Three groups of trauma patients, who received more than 10 units of packed
red blood cells (PRBC), were compared: a pre-MTP group (2002–2006), an MTP-I group
(2006–2010) and an MTP-II group (2010–2016) when the protocol was updated. Key out-
comes were mortality, complications and number of blood products transfused.
Results: A total of 168 patients were included: 54 pre-MTP patients were compared to
47 MTP-I and 67 MTP-II patients. In the MTP-II group, fewer units of PRBC and platelets
were administered within the first 24 h: 17 versus 14 (P = 0.01) and 12 versus
8 (P < 0.001), respectively. Less infections were noted in the MTP-I group: 51.9% versus
31.9% (P = 0.04). No significant differences were found regarding mortality, ventilator
days, intensive care unit and total hospital lengths of stay.
Conclusion: Introduction of an MTP-II in our level 1 civilian trauma centre significantly
reduced the amount of PRBC and platelets used during damage control resuscitation. Introduc-
tion of the MTP did not directly impact survival or the incidence of complications. Nevertheless,
this study reflects the complexity of real-life medical care in a level 1 civilian trauma centre.
Introduction
Haemorrhagic shock is consistently the second-leading cause of early
deaths in trauma, second only to central nervous system injury.1,2 In
trauma patients, priority lies with early haemorrhage control and res-
toration of blood volume and coagulation. Bleeding patients that do
not or barely respond to fluid therapy have exsanguinating injuries.2
In these patients, a massive transfusion can be life-saving. Massive
transfusion is usually defined as transfusion of more than 10 packed
red blood cells (PRBC) within 24 h.3
Massively transfused patients often present with early and pro-
found coagulopathy. Up to 25% of these patients have significant
coagulopathy upon arrival to hospital.4 In the hectic clinical situa-
tion of exsanguination, massive transfusion is often performed
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empirically, not guided by blood tests.2 Contemporary evidence
suggests that outcomes are improved when PRBC, fresh frozen
plasma (FFP) and platelets (PLTs) are transfused in predefined
ratios.4–6 These predefined transfusion ratios and timing for labora-
tory tests are described in a massive transfusion protocol (MTP).
Once the protocol is activated, the blood bank provides rapid and
timely delivery of all blood products to facilitate resuscitation.
Over time, MTPs have become standard practice for level 1
trauma centres, even though these protocols vary significantly and
have not always been associated with improved mortality in before-
and-after studies.6–8 Nunez et al.9 noted that only 3–5% of all
trauma admissions will require massive transfusion. Consequently,
in the busiest trauma centres, with 2000 trauma admissions annu-
ally, exposure is unlikely to exceed 100 patients per year. This
study examines the effect of an MTP in an Australian level 1 trauma
centre with 300 major trauma admissions (Injury Severity Score
(ISS) >15) and approximately 12 massively transfused patients per
year. The aim was to evaluate the evolution of the MTP in an urban
level 1 trauma centre with lower exposure to life-threatening trau-
matic haemorrhage than the larger international trauma centres
reflected in the current literature.
Methods
An observational study was performed in Liverpool Hospital, Syd-
ney, Australia, a level 1 trauma centre. Three groups of trauma
patients who underwent massive transfusion were compared: a pre-
MTP group (2002–2006), a group treated according to MTP-I
(2006–2010) and a group treated according to MTP-II (2010–2016)
(Fig. S1).
Trauma patients who were massively transfused were identified
through the Liverpool Hospital Trauma Registry and the Blood
Bank Registry. Data collection was undertaken prospectively by a
limited group of three specially trained nurses. The Sydney South
West Area Health Service Human Research Ethics Committee
approved the research design.
Massive transfusion protocol
The first MTP for trauma at Liverpool Hospital became active on
1 February 2006. This MTP-I could be activated by a doctor calling
the blood bank or by the blood bank staff when noticing dispatch
of the fifth unit of PRBC in a 2-h period. The MTP provided for
empiric administration of FFP and PLTs (one pooled bag consists
of four single donor PLT units) after the first 6 units of PRBC.
Criteria for the use of recombinant activated factor VII (rFVIIa)
and other management options were embedded (Appendix S1).
Before 2010 a transfusion ratio of PRBC : FFP : PLTs = 6:4:1
was used, based on the literature available at the time (Appendix
S1). In 2010 the MTP was reviewed and updated to a ratio of
PRBC : FFP = 1:1 because of a survival advantage identified in the
literature.10,11 With activation of the updated MTP-II in 2010, four
pre-thawed units of FFP were dispatched with 4 units of PRBC.
Then every subsequent shipment contained 4 units of red cells and
4 units of FFP, and alternating one pooled PLTs pack and 5 units
of cryoprecipitate or only 5 units of cryoprecipitate (Appendix S2).
Patients and characteristics
Included were all trauma patients who received massive transfusion
between January 2002 and July 2016. Massive transfusion was
defined as having received 10 or more units of PRBC within 24 h
of admission and the first blood product within 6 h of admission.
Trauma patients where MTP was activated because of another
cause not directly related to trauma were excluded.
Clinical, laboratory and outcome parameters were extracted as
well as time-interval and transfusion data by using the mentioned
registries, individual patient notes and electronic patient files. Char-
acteristics included age, gender, trauma mechanism, systolic blood
pressure, heart rate, pH, haemoglobin level, PLT count and pre-
hospital fluid volume.
Compliance
The average transfusion ratio was calculated, as was the percentage
in which protocol target ratios were reached. In addition, the per-
centage of PRBC : FFP ratios of 3:1 or higher were scored as these
appear to be associated with a worse outcome.12
Outcomes
Mortality at 24 h hospital discharge, ventilator and intensive care
unit (ICU) days and complications were analysed. Abdominal com-
partment syndrome (ACS) was defined as sustained intra-abdominal
pressure of more than 20 mmHg associated with new organ dysfunc-
tion or organ failure. Multiple organ dysfunction syndrome
(MODS) as the development of progressive and potentially revers-
ible physiological dysfunction in three or more organs.13 Infection
as a clinically relevant and/or culture positive diagnosis identified
by the treating doctor. The number of blood products that were
administered within the first 24 h through to the end of ICU stay
was scored. Interval times were measured from time of arrival in
the emergency department through to the administration of the
first blood product. Data sets were checked for completeness
before statistical analysis.
Statistical analyses
Parametric data were presented as mean  standard deviation,
whereas non-parametric data were presented as median plus
range. For normally distributed data the Student’s t-test was used
to compare groups. Comparisons for categorical data were per-
formed using chi-squared analysis. In case of skewed distribu-
tion of data, the Mann–Whitney U-test was used. Analyses of
variance and Kruskal–Wallis test were used to compare all three
groups (SPSS 16, Chicago, IL, USA). Statistical significance
was set to P-values <0.05.
Results
Patients and characteristics
During the period of 1 January 2002 until 31 July 2016 a total of
4432 major trauma patients (ISS >15) were admitted. Of these,
168 patients met the study inclusion criteria for massive transfusion.
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All groups were comparable regarding age, gender, mechanism of
injury, ISS, systolic blood pressure, pH, PLT count and the adminis-
tered volume of pre-hospital fluids upon emergency department
arrival, except for haemoglobin level which was higher in the MTP-II
group (114 versus 113 versus 123 mmoL/L, P = 0.04; Table S1).
Compliance
The average PRBC : FFP ratio in the 47 patients in theMTP-I groupwas
1.92:1; for the 67 patients in the MTP-II group this was 1.94:1. Fourteen
(29.8%) patients of the MTP-I group met the PRBC : FFP transfusion
ratio of 6:4, and one (2.1%) patient met the PRBC : FFP : PLTs ratio of
6:4:1. Fifty-two (77.6%) patients of theMTP-II groupmet a PRBC : FFP
transfusion ratio of 1:1, and 39 (58.2%) patientsmet a PRBC :FFP : PLTs
ratio of 1:1:1. In the pre-MTPgroup 19 (35.2%) patients had PRBC : FFP
transfusion ratios higher than 3:1. In the MTP-I and MTP-II groups, six
(12.8%) patients and 13 (19.4%) patients had transfusion ratios higher
than 3:1 (P = 0.35; Table S2).
Outcomes
Mortality 24 h following admission did not differ between pre-
MTP and MTP-I groups: 29.6% versus 29.8% (P = 0.99). No dif-
ferences were found regarding the number of days patients were in
ICU and the total number of ventilator days and hospital length of
stay. Although the incidence of ACS and MODS was comparable
between groups, the incidence of infections was significantly lower
in the MTP-I group when compared to the pre-MTP group (51.9%
versus 31.9%, P = 0.04).
Mortality 24 h following admission did not significantly differ
between the MTP-I and MTP-II groups: 29.8% versus 38.8%
(P = 0.32). Mortality through to hospital discharge was similar:
42.6% versus 49.3% (P = 0.48). Furthermore, no differences were
found regarding ICU lengths of stay, ventilator days and hospital
lengths of stay between groups: 21 versus 7 hospital days
(P = 0.37). Moreover, the incidence of ACS, MODS and infections
did not differ between the groups (Table S3).
Amount of blood products
The number of blood products administered within 24 h of admis-
sion and during the ICU stay did not differ between the pre-MTP
group and the MTP-I group (Table S4). However, significantly
fewer units of PRBC were administered within the first 24 h of
admission and throughout the ICU stay, in the MTP-II group com-
pared to the MTP-I group: 14 versus 17 (P = 0.01) and 16 versus
21 (P > 0.001), respectively. The number of administered units of
PLTs within the first 24 h and in total was significantly lower in the
MTP-II group compared to the MTP-I group: 8 versus 12 (P < 0.001)
and 8 versus 12 (P = 0.01), respectively.
Regarding the administration of rFVIIa, it was significantly less
frequently administered in the MTP-II group compared to the
MTP-I group: 9.0% versus 27.7% (P = 0.01). There was no differ-
ence between groups regarding the administration of FFP within
24 h and in total until the end of ICU stay (Table S4).
The time interval between admission and administration of the
first blood product seemed to improve in the MTP-II group,
although the difference was not significant: MTP-I versus MTP-II;
19 versus 14 min (P = 0.08; Table S5). No difference was found
between the pre-MTP and the MTP-I groups; 18 versus 19 min
(P = 0.45; Table S5).
Discussion
Massive transfusion plays a crucial role in resuscitating patients
with exsanguinating injuries, though scientific reports on the effect
of MTPs are contradictory.14 As a result, MTPs differ between
institutions, and the effect of the protocols varies as well. A meta-
analysis in 2013 of observational studies in trauma centres with
exposure to massive haemorrhage on average 40 cases a year,
showed no benefit of introduction of an MTP.15
Survival
In our study, introduction of an MTP did not improve survival in
massively transfused trauma patients. The low number of patients
in the MTP-II group (39/67 patients, 58.2%) in which the target
transfusion ratio of 1:1:0.5 (PRBC : FFP : PLTs) was reached, may
be a significant aspect to this result. However, this study and its
outcomes are a reflection of real-life medicine where an MTP could
give guidance in the hectic clinical situation of exsanguination, yet
it might not always be attainable. Exposure to trauma patients with
massive transfusion in our hospital averaged 10–12 patients per
year and this seems limited compared to bigger centres that did find
a survival advantage.15 However, even in the busiest civilian
trauma centres, the number of patients that receive massive transfu-
sion is likely to be less than 100 patients per year.16
Compliance
The absence of clear recommendations in the MTP field may lead
to poor compliance.17 Cotton et al.7 found that only 27% of all
trauma exsanguination protocol activations had full compliance
during a performance improvement investigation and compliance
could only be improved to a maximum of 50%. Bawazeer et al.17
found a mean compliance rate of 66% with a clear association
between survival and a higher level of compliance. The retrospec-
tive design of our study did not allow us to evaluate compliance to
our MTP. However, besides the low number of patients in which
the target transfusion ratio was reached, 12.8% in the MTP-I and
19.4% in MTP-II group had transfusion ratios higher than 3:1.
According to Johansson et al.,12 in that case early outcome was
much worse with an early mortality of 57%. Thus, when inter-
preting our findings poor compliance to the MTP should be taken
into account. Although challenging in a level 1 trauma centre with
only one to two MTP cases per month, increasing protocol compli-
ance should be a priority as it may save lives.
Amount of blood products
In the MTP-II group, a decrease in blood product usage was found.
This is consistent with other studies.6,7 The intended target ratio of
these studies was PRBC : FFP : PLTs of 1:1:1, which might explain
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why the same decrease was not found in the MTP-I group with a
target ratio of 6:4:1.
Unlike other studies, no difference was found in FFP usage in
the MTP-II group. Until 2010 already thawed FFP, like in other
MTPs, was not available on demand in our hospital.18 Hence, it is
possible that patients in the MTP-I group may not have received
sufficient numbers of FFP in a timely fashion, while transfusing
PRBC. Furthermore, the lower usage of PLTs we found, may have
been affected by the introduction of cryoprecipitate to the MTP in
2008. As an effect, fewer units of PLTs were transfused. This may
in turn bias the effect of the MTP-II on the lower usage of PLTs.
We expected that introduction of the MTP would reduce the time
between admission and administration of the first blood product.
However, the reduction found in this study appeared statistically
not significant, which could in part be due to low compliance.
Aside from a blood utilization and cost standpoint, the reduction in
blood product usage may potentially lead to a reduction in morbid-
ity among survivors as lower blood product administration is asso-
ciated with fewer complications.7
Recombinant factor VIIa
Recombinant factor VIIa (NovoSeven; Novo Nordisk, Bagsvaerd,
Denmark) was used as a ‘last resort’ for the treatment of coagulopathy
in trauma patients since 2003.19,20 However, the CONTROL trial was
terminated early in 2010 because of futility, and rFVIIa became less
popular.21 Congruent with this result, the use of rFVIIa was found to
be lower in our MTP-II group compared to prior.
Hospital stay and complications
No differences were found regarding ICU and hospital lengths of
stay, and ventilator days, in contrast to the study of Cotton et al.7
The same study also found a decrease in the number of complica-
tions, such as ACS, MODS and infections after introduction of an
MTP. Our study did find a significant decrease in the number of
infections in the MTP-I group compared to the pre-MTP group.
However, since no other differences were found between groups,
our finding may not be associated with the implementation of
aMTP but rather improvements in trauma care overall, and specific
aspects of ICU care may be responsible.22
Limitations
Our study is a single centre, observational study with the limitations
of all retrospective registry reviews introducing information bias;
however, data collection for the Liverpool Hospital Trauma Registry
was done prospectively and by a limited group of three specially
trained nurses, which contributes positively to the validity of our
data. Additionally, survival bias and reverse survival bias should be
taken into account, as severely injured patients may have died before
they received a 10th unit of PRBC, or achieved haemostasis and
therefore received less than 10 PRBC, and were therefore excluded.
During the years covering this study, tranexamic acid, prothrom-
bin complex concentrates and cryoprecipitate became increasingly
used and may have affected treatment and outcomes. Furthermore,
the use of ventilator and ICU days as an outcome can be challenging
as many patients die before extubation or ICU discharge. The con-
cept of ventilator- and ICU-free days has been proposed as an alter-
native combining mortality and mechanical ventilation duration.
However, Bodet-Contentin et al.23 concluded that use of ventilator-
free days as an outcome has many drawbacks.
Despite the power of this study is limited, due to the relatively
small sample size, the use of historic controls and the high protocol
failure, it does reflect the realities of MTP use in an Australian
major trauma centre and may reflect common practice at civilian
level 1 trauma centres with similar exposure.
Recommendations
Survival improves significantly when the target ratio of PRBC :
FFP : PLTs of 1:1:1 is reached.18,24 Therefore, at a local level, fur-
ther effort is needed to improve both the MTP design and the logis-
tics of its implementation so the target ratio is more often realized.
Improving compliance to the protocol should be priority, as compli-
ance independently improves survival.17 To that end, a human
factors-supported approach could be used to guide the design and
implementation of a new support system for MTP to optimize the
practice and performance of trauma and blood bank staff by gather-
ing qualitative and quantitative data on current clinical practice
regarding damage control resuscitation.25 This approach may lead
to more successful implementation of an updated MTP by promot-
ing good decision support, providing different options for getting
consistent and improved outcomes and offering a way to measure
the effects of these types of complex interventions.25
Ongoing data collection will allow us to analyse outcomes in
some of the subgroups and may allow for a more precise determina-
tion of the effect of an MTP. Recently, literature on MTP is care-
fully recommending the implementation of viscoelastic haemostatic
assays such as thromboelastography and thromboelastometry in the
protocol.26 Mortality improved as an effect of goal-directed resusci-
tation in at least one study according to Stensballe et al.27 Closely
monitoring the results of the ongoing trial on this topic is rec-
ommended as results so far are promising.
Conclusion
Initial introduction of an MTP (MTP-I) did not affect survival,
blood product usage or the incidence of patient complications in
this Australian level 1 civilian trauma centre. However, the intro-
duction of an updated MTP (MTP-II) significantly reduced blood
product usage though there remained no discernible effect on
patient mortality, or the incidence of complications.
Although an MTP can give guidance in the hectic clinical situa-
tion of exsanguination, precise and exact MTP compliance in
real-life medicine can be challenging. The results from this study
demonstrate MTP effect in a moderate volume environment and
may be useful in similar trauma system settings. Although this
study demonstrates issues in MTP compliance which need atten-
tion, there are also encouraging results with regard to decreased
blood product usage. Further efforts towards improved MTP
compliance are warranted.
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